by Dana-Farber Cancer Institute New research shows that genetics account for only five to 10 per cent of risk for most human diseases, and that gene testing is a poor predictor of whether someone will develop diseases including diabetes, Alzheimer’s and many types of cancer. Credit: CC0 Public Domain A three-drug combination that sent chronic...
by Dana-Farber Cancer Institute Credit: CC0 Public Domain A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute. “Patients who received the kinase inhibitor cabozantinib in addition to checkpoint-blockers nivolumab and ipilimumab experienced...
MASSACHUSETTS GENERAL HOSPITAL BOSTON – Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer, a disease that is fatal in most cases. The study, which was conducted by a team led by investigators at...
